The newly minted combination HIV drug from Gilead Sciences and Johnson & Johnson, Complera, is expected to bring in more than $500 million annually. Release | Report
The newly minted combination HIV drug from Gilead Sciences and Johnson & Johnson, Complera, is expected to bring in more than $500 million annually. Release | Report